Back

Real world experience of sacubitril/valsartan: insights on tolerability and outcome from a specialised heart failure clinic

2 September 2019 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 4 - Heart failure treatment, HFpEF, HFmrEF Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Kai Neoh

Aintree University Hospital, Liverpool (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Associate Professor H. Fukuta (Nagoya, JP)
Abstract
Presentation thumbnail
Professor L. Tumasyan (Yerevan, AM)
Abstract Slides
Presentation thumbnail
Doctor C. Wei-Ting (Tainan, TW)
Abstract Slides
Presentation thumbnail
Doctor K. Tsukamoto (Tokyo, JP)
Abstract
Presentation thumbnail
Professor J. Spinar (Brno, CZ)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 4 - Heart failure treatment, HFpEF, HFmrEF

The Event

Event poster

ESC Congress 2019

2 September 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Evaluating tolerability and patient outcomes of sacubitril/valsartan for the management of heart failure with reduced ejection fraction within a pharmacist led clinic at a cardiovascular tertiary cent
29 June 2021
thumbnail
Congress Presentation
Small reductions in NTproBNP levels in outpatients treated with sacubitril-valsartan reduce hospitalizations and emergency room visits.
29 June 2021
thumbnail
Congress Session
Latest science in heart failure 1
27 August 2022
thumbnail
ESC Journals
Real world evidence of Sacubitril/Valsartan in octogenarian patients with heart failure. Results From the PARACHUTE-HF Study
28 October 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources